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Idiosyncratic drug-induced liver injury (DILI) is an 
important cause of liver failure and liver injury leading to 
transplantation, although in most cases self-remitting when 
administration of the offending drug is stopped (1-3). In 
rare cases DILI can lead to a persistent/chronic form of 
injury (4). 
According to Hy’s law drug-induced jaundice caused by 
a hepatocellular injury, leads to death from liver failure or 
need for a liver transplantation in approximately 10% of 
cases (2,3). When Hy’s law cases with ALT > 3× upper limit 
of normal (ULN) and serum bilirubin >2 ULN occur in 
clinical trials it is usually predictive of severe hepatotoxicity 
post marketing. 
There has though been a lack of studies where the role 
of DILI in death or LT is further characterized.
The article by Hayashi et al. published recently in 
Hepatology (5) is one of many important publications from 
the DILIN group in recent years. The DILIN network is a 
multicenter prospective DILI study which started recruiting 
patients in 2004. It consists of eight academic centers in the 
United States and a data-coordinating center sponsored by 
the National Institute of Health (5). 
The DILIN group had previously published their 
findings on the prognosis of 660 DILI patients 6 months 
after onset of DILI, where 9.4% of patients died or 
underwent liver transplantation (6). 
In this study Hayashi et al., 107 of 1,098 patients with 
DILI died or needed liver transplantation 2 years after 
diagnosis of DILI. The all cause fatality rate was 9.6% and 
DILI-related fatality rate 7.6%. The percentage of Hy’s law 
cases with hepatocellular damage and jaundice was 10%, 
which in is in line with results from previous studies (2,3). 
The nR modification of Hy’s law proposed by Robles-
Diaz et al. (7) yielded a higher percentage, 14%, so the nR 
version might offer some improvement beyond the original 
version when used in a clinical setting. 
Patients who died or had l iver transplant were 
significantly older and had higher BMI (5). Interestingly a 
lower proportion of patient who had poor outcome had a 
“definitive” or “highly likely” causality assessment, possibly 
because of the recovery phase being truncated by death like 
the authors state, but no data are provided regarding the 
causality score that can confirm this statement due to the 
causality assessment method used.
Like Hayashi et al. acknowledged in the paper categorization 
of primary versus contributory cause of death could be 
very difficult, as some of the patients were terminally ill 
when they developed DILI. In most cases these patients 
were included because DILI hastened the progression 
of their illness and contributed to their death. Although 
it was a difficult task to categorize these cases, it was 
important to include cases with a potential contributory 
cause of death as a large proportion of the disease burden 
can be observed in this group of patients. The authors 
defined a contributory role as one of the followings: (I) 
DILI left the patient in weakened or malnourished state 
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which contributed to death by another disease; (II) DILI 
prevented necessary care of another fatal illness; (III) 
DILI exacerbated or was part of another concurrent 
illness and (IV) the death was due to a complication from 
a test or a procedure done to evaluate DILI. The second 
category might be a highly underestimated one. Patients 
with potentially terminal diseases are often on potentially 
hepatotoxic drug (e.g., cancer patients) and a forced 
alteration in treatment due to DILI can have a profound 
effect on prognosis. 
One of the strengths of the current study was the 
categorization of patients that proceeded to liver 
transplantation or had fatal liver injury primarily due to 
DILI. The four categories were acute liver failure (ALF), 
acute-on-chronic liver failure (ACLF), acute cholestatic 
liver failure and chronic liver failure. Most cases (50/68) 
were ALF, of whom 83% had a hepatocellular pattern. In 
five cases, patients had underlying cirrhosis and DILI as 
a primary cause of death. Nine patients had DILI-related 
chronic liver failure, needing liver transplantation >26 
weeks after DILI onset, but no information was provided 
whether these patients had available baseline liver tests prior 
to the diagnosis of DILI, and whether other possible causes 
of chronic liver injury were excluded. 
Herbal and dietary supplements (HDS) were important 
causes of liver injury requiring liver transplantation or liver 
related death. Overall 14/68 (21%) of deaths were due to 
HDS, 9/50 (18%) ALF, 2/5 (40%) ACLF and 3/9 (33%) 
chronic liver failure. Unfortunately names of the herbal/
dietary supplements were not provided in the supplemental 
tables.
A number of variables were significantly associated with 
fatalities or liver transplantation. Understandably, markers 
of liver dysfunction were associated worse outcome on 
multivariate analysis: higher total bilirubin and serum ALT, 
lower albumin and thrombocytopenia. Elevated white blood 
cells (WBC) which was associated with poor outcome could 
reflect acute systemic illness or concurrent infection.
Chronic liver failure was associated with death or liver 
transplantation in univariate analysis but not in multivariate 
analysis, which is agreement with two previous studies by 
the DILIN group (6,8). It is conceivable, like the authors 
point out, that this is due to lack of power. Another likely 
explanation is that only patients with more advanced liver 
disease are in increased risk of death/LT after DILI, patients 
with preexisting liver disease were no stratified according to 
severity of the disease in this study. This will hopefully be 
addressed in further studies.
Steven-Johnson syndrome (SJS) and DRESS (drug 
reaction with eosinophilia and systemic symptoms) was 
associated with being higher risk of death or LT in a 
univariate but not multivariate analysis. This association is 
in line with high mortality in these drug reactions (9-11). 
In SJS mortality is higher in those with severe hepatic 
dysfunction (10) although it is unclear whether this is due 
to the effects of the idiosyncratic drug reaction on the 
liver or if those more severely affected by SJS develop liver 
dysfunction secondary to sepsis.
It is unclear why Asian race was associated with worse 
outcome. Alcohol intake was not mentioned in the paper (5), 
once found to be associated with less severity of liver injury 
although these findings were most likely to reporting bias 
and not reproduced in later papers (8).
In this study on a large cohort of DILI patents 
the DILIN confirmed the previous results regarding 
prognosis and risk factors of DILI. The authors are to 
be congratulated for the thorough analysis and detailed 
phenotypic information on their patients provided in 
the paper. Important classification of primary role and 
contributory role of DILI in the death of these patients was 
introduced and provides insight on the role of idiosyncratic 
liver injury on prognosis in these patients.
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